Transcera

Transcera is pioneering a new class of targeted protein degraders that act on extracellular proteins using ceramide-based molecules called DICers. Built on Harvard-discovered sphingolipid biology, its modular platform enables ligand-directed degradation across diverse targets beyond the reach of traditional PROTACs. By harnessing a natural lysosomal pathway, Transcera aims to unlock new treatments for immune and inflammatory diseases driven by extracellular proteins.